Table SA1. Clinical data of MET-Amp Patients who received ICI (Rizvi et.al, n=4)

|  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| **PATIENT\_ID** | **SAMPLE\_ID** | **SEX** | **AGE** | **SMOKER** | **LINES\_OF\_TX** | **IRB** | **TREATMENT\_TYPE** | **PFS\_MONTHS** | **PFS\_STATUS** | **DURABLE\_CLINICAL\_BENEFIT** | **GENE\_PANEL** | **ONCOTREE\_CODE** | **MUTATION\_RATE** | **FGA** | **PDL1\_SCORE** | **CANCER\_TYPE** | **CANCER\_TYPE\_DETAILED** | **MET** |
| P-0007582 | P-0007582-T01-IM5 | Male | 82 | Ever | 2 | Commercial | Monotherapy | 1.03 | Progressed | NO | IMPACT410 | LUAD | 4.717 | 0.41 | NA | Non-Small Cell Lung Cancer | Lung Adenocarcinoma | MET-Amp |
| P-0003119 | P-0003119-T01-IM5 | Male | 53 | Ever | 5 | Commercial | Monotherapy | 5.57 | Progressed | NO | IMPACT410 | LUAD | 12.2642 | 0.1 | NA | Non-Small Cell Lung Cancer | Lung Adenocarcinoma | MET-Amp |
| P-0015296 | P-0015296-T01-IM6 | Male | 67 | Ever | 1 | Commercial | Monotherapy | 6.43 | Not Progressed | YES | IMPACT468 | NSCLC | 18.8525 | 0.2 | 100 | Non-Small Cell Lung Cancer | Non-Small Cell Lung Cancer | MET-Amp |
| P-0005320 | P-0005320-T01-IM5 | Male | 47 | Ever | 2 | Commercial | Monotherapy | 6.57 | Progressed | YES | IMPACT410 | LUAD | 7.5472 | 0 | NA | Non-Small Cell Lung Cancer | Lung Adenocarcinoma | MET-Amp |

Table SA2. Clinical data of MET-Amp Patients who received ICI (local cohort, n=13)

|  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| **PATIENT\_ID** | **PFS\_Status** | **PFS\_Time (Month)** | **TMB** | **Lines\_of\_Treatment** | **Drug\_Name** | **Birth\_Date** | **Clinical\_Stage** | **Sex** | **Immunotherapy** | **Sample\_Type** | **Best\_overall\_response(>6 weeks)** | **Histology** | **CANCER\_TYPE\_DETAILED** | **MET (Copy Number Alterations)** |
| P1 | Progressed | 1.5 | 11.4 | 4 | Sintilimab | 1966/9/16 | IV | Male | YES | Tissue+Blood | PD | NSCLC | non-small-cell lung cancer not otherwise specified | MET-Amp |
| P2 | Progressed | 1.5 | 7.9 | 4 | Sintilimab | 1953/7/29 | IV | Male | YES | Tissue+Blood | PD | LUAD | Lung Adenocarcinoma | MET-Amp |
| P3 | Progressed | 2 | 24.3 | 3 | pembrolizumab | 1950/5/13 | IV | Male | YES | Tissue+Blood | PD | LUAD | Lung Adenocarcinoma | MET-Amp |
| P4 | Not Progressed | 4 | 5.7 | 3 | sintilimab | 1954/8/28 | IV | Female | YES | Tissue+Blood | SD | LUAD | Lung Adenocarcinoma | MET-Amp |
| P5 | Not Progressed | 4 | 61.9 | 3 | pembrolizumab | 1964/11/14 | IV | Male | YES | Tissue+Blood | PR | LUAD | Lung Adenocarcinoma | MET-Amp |
| P6 | Not Progressed | 7.8 | 11.4 | 3 | nivolumab | 1954/5/13 | IV | Male | YES | Blood | PR | LUSC | Lung Squamous Cell Carcinoma | MET-Amp |
| P7 | Not Progressed | 4.5 | 16.4 | 3 | nivolumab | 1960/12/8 | IV | Male | YES | Tissue+Blood | PR | NSCLC | non-small-cell lung cancer not otherwise specified | MET-Amp |
| P8 | Not Progressed | 5.2 | 12.9 | 3 | Sintilimab | 1939/11/7 | IV | Male | YES | Blood | PR | LUSC | Lung Squamous Cell Carcinoma | MET-Amp |
| P9 | Not Progressed | 5.5 | 22.1 | 4 | pembrolizumab | 1960/4/1 | IV | Male | YES | Blood | SD | LUAD | Lung Adenocarcinoma | MET-Amp |
| P10 | Not Progressed | 5 | 15.7 | 4 | nivolumab | 1962/3/5 | IV | Male | YES | Blood | SD | LUAD | Lung Adenocarcinoma | MET-Amp |

Table SA3. Clinical data of Not MET-Amp Patients who received ICI (Rizvi et.al, n=236)

|  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| **PATIENT\_ID** | **SAMPLE\_ID** | **SEX** | **AGE** | **SMOKER** | **LINES\_OF\_TX** | **IRB** | **TREATMENT\_TYPE** | **PFS\_MONTHS** | **PFS\_STATUS** | **DURABLE\_CLINICAL\_BENEFIT** | **GENE\_PANEL** | **ONCOTREE\_CODE** | **MUTATION\_RATE** | **FGA** | **PDL1\_SCORE** | **CANCER\_TYPE** | **CANCER\_TYPE\_DETAILED** | **MET** |
| P-0000012 | P-0000012-T03-IM3 | Female | 58 | Ever | 1 | Clinical trial | Combination | 27.2 | Not Progressed | YES | IMPACT341 | LUAD | 30.6122 | 0.18 | NA | Non-Small Cell Lung Cancer | Lung Adenocarcinoma | Not MET-Amp |
| P-0000082 | P-0000082-T01-IM3 | Male | 60 | Ever | 4 | Clinical trial | Monotherapy | 14.5 | Progressed | YES | IMPACT341 | LUAD | 1.0204 | 0.36 | 100 | Non-Small Cell Lung Cancer | Lung Adenocarcinoma | Not MET-Amp |
| P-0000208 | P-0000208-T01-IM3 | Female | 68 | Ever | 1 | Clinical trial | Monotherapy | 4.17 | Progressed | NO | IMPACT341 | LUAD | 2.0408 | 0.12 | 3 | Non-Small Cell Lung Cancer | Lung Adenocarcinoma | Not MET-Amp |
| P-0000235 | P-0000235-T01-IM3 | Male | 77 | Ever | 3 | Commercial | Monotherapy | 0.6 | Progressed | NO | IMPACT341 | LUSC | 8.1633 | 0.24 | NA | Non-Small Cell Lung Cancer | Lung Squamous Cell Carcinoma | Not MET-Amp |
| P-0000299 | P-0000299-T01-IM3 | Male | 66 | Ever | 2 | Clinical trial | Combination | 1.63 | Progressed | NO | IMPACT341 | LUNE | 7.1429 | 0.01 | NA | Non-Small Cell Lung Cancer | Large Cell Neuroendocrine Carcinoma | Not MET-Amp |
| P-0000302 | P-0000302-T02-IM6 | Male | 67 | Ever | 3 | Commercial | Monotherapy | 4.93 | Not Progressed | NE | IMPACT468 | LUSC | 7.377 | 0.05 | 0 | Non-Small Cell Lung Cancer | Lung Squamous Cell Carcinoma | Not MET-Amp |
| P-0000363 | P-0000363-T01-IM3 | Male | 71 | Never | 2 | Clinical trial | Monotherapy | 1.2 | Progressed | NO | IMPACT341 | LUSC | 11.2245 | 0.14 | NA | Non-Small Cell Lung Cancer | Lung Squamous Cell Carcinoma | Not MET-Amp |
| P-0000458 | P-0000458-T01-IM3 | Male | 66 | Ever | 6 | Commercial | Monotherapy | 1.73 | Progressed | NO | IMPACT341 | LUAD | 1.0204 | 0 | NA | Non-Small Cell Lung Cancer | Lung Adenocarcinoma | Not MET-Amp |
| P-0000563 | P-0000563-T01-IM3 | Male | 42 | Never | 1 | Clinical trial | Monotherapy | 1.5 | Progressed | NO | IMPACT341 | LUAD | 3.0612 | 0.11 | 0 | Non-Small Cell Lung Cancer | Lung Adenocarcinoma | Not MET-Amp |
| P-0000604 | P-0000604-T01-IM3 | Male | 57 | Never | 1 | Clinical trial | Combination | 11.83 | Progressed | YES | IMPACT341 | LUAD | 4.0816 | 0.03 | 0 | Non-Small Cell Lung Cancer | Lung Adenocarcinoma | Not MET-Amp |
| P-0000670 | P-0000670-T01-IM3 | Female | 49 | Ever | 1 | Clinical trial | Combination | 2.33 | Progressed | NO | IMPACT341 | LUAD | 6.1224 | 0.02 | NA | Non-Small Cell Lung Cancer | Lung Adenocarcinoma | Not MET-Amp |
| P-0000681 | P-0000681-T02-IM5 | Female | 68 | Ever | 3 | Commercial | Monotherapy | 5.47 | Progressed | NO | IMPACT410 | LUAD | 22.6415 | 0.04 | 50 | Non-Small Cell Lung Cancer | Lung Adenocarcinoma | Not MET-Amp |
| P-0000689 | P-0000689-T02-IM5 | Male | 58 | Ever | 6 | Commercial | Monotherapy | 2.57 | Progressed | NO | IMPACT410 | LUAD | 2.8302 | 0.07 | NA | Non-Small Cell Lung Cancer | Lung Adenocarcinoma | Not MET-Amp |
| P-0000731 | P-0000731-T01-IM3 | Female | 73 | Ever | 1 | Clinical trial | Monotherapy | 10 | Progressed | YES | IMPACT341 | LUAD | 6.1224 | 0.47 | 100 | Non-Small Cell Lung Cancer | Lung Adenocarcinoma | Not MET-Amp |
| P-0000826 | P-0000826-T01-IM3 | Male | 64 | Ever | 1 | Clinical trial | Combination | 3.8 | Progressed | NO | IMPACT341 | LUSC | 4.0816 | 0.05 | 2 | Non-Small Cell Lung Cancer | Lung Squamous Cell Carcinoma | Not MET-Amp |
| P-0000894 | P-0000894-T01-IM3 | Male | 79 | Never | 3 | Clinical trial | Monotherapy | 5.27 | Progressed | NO | IMPACT341 | LUAD | 6.1224 | 0.29 | NA | Non-Small Cell Lung Cancer | Lung Adenocarcinoma | Not MET-Amp |
| P-0000913 | P-0000913-T02-IM5 | Female | 58 | Never | 7 | Commercial | Monotherapy | 3.5 | Progressed | NO | IMPACT410 | LUAD | 3.7736 | 0.14 | 0 | Non-Small Cell Lung Cancer | Lung Adenocarcinoma | Not MET-Amp |
| P-0000978 | P-0000978-T02-IM5 | Female | 59 | Never | 3 | Commercial | Monotherapy | 2.1 | Progressed | NO | IMPACT410 | LUAD | 8.4906 | 0.37 | 0 | Non-Small Cell Lung Cancer | Lung Adenocarcinoma | Not MET-Amp |
| P-0001093 | P-0001093-T01-IM3 | Male | 65 | Ever | 1 | Clinical trial | Combination | 22.43 | Progressed | YES | IMPACT341 | LUAD | 11.2245 | 0 | 10 | Non-Small Cell Lung Cancer | Lung Adenocarcinoma | Not MET-Amp |
| P-0001121 | P-0001121-T01-IM3 | Female | 44 | Ever | 2 | Clinical trial | Monotherapy | 1.17 | Progressed | NO | IMPACT341 | LUNE | 1.0204 | 0.49 | NA | Non-Small Cell Lung Cancer | Large Cell Neuroendocrine Carcinoma | Not MET-Amp |
| P-0001171 | P-0001171-T01-IM3 | Male | 53 | Ever | 2 | Commercial | Monotherapy | 13.17 | Progressed | YES | IMPACT341 | LUAD | 91.8367 | 0.52 | NA | Non-Small Cell Lung Cancer | Lung Adenocarcinoma | Not MET-Amp |
| P-0001340 | P-0001340-T01-IM3 | Male | 62 | Ever | 3 | Commercial | Monotherapy | 5.33 | Progressed | NO | IMPACT341 | NSCLC | 6.1224 | 0.04 | 30 | Non-Small Cell Lung Cancer | Non-Small Cell Lung Cancer | Not MET-Amp |
| P-0001365 | P-0001365-T02-IM3 | Male | 71 | Ever | 3 | Commercial | Monotherapy | 1.87 | Progressed | NO | IMPACT341 | LUAD | 11.2245 | 0.09 | NA | Non-Small Cell Lung Cancer | Lung Adenocarcinoma | Not MET-Amp |
| P-0001385 | P-0001385-T01-IM3 | Female | 50 | Ever | 1 | Clinical trial | Combination | 30.43 | Not Progressed | YES | IMPACT341 | LUAD | 13.2653 | 0.01 | 80 | Non-Small Cell Lung Cancer | Lung Adenocarcinoma | Not MET-Amp |
| P-0001633 | P-0001633-T01-IM3 | Female | 55 | Never | 3 | Commercial | Monotherapy | 0.67 | Progressed | NO | IMPACT341 | LUAD | 4.0816 | 0.17 | 0 | Non-Small Cell Lung Cancer | Lung Adenocarcinoma | Not MET-Amp |
| P-0001665 | P-0001665-T01-IM3 | Female | 48 | Never | 6 | Commercial | Monotherapy | 3.07 | Progressed | NO | IMPACT341 | LUAD | 1.0204 | 0.07 | NA | Non-Small Cell Lung Cancer | Lung Adenocarcinoma | Not MET-Amp |
| P-0001830 | P-0001830-T01-IM3 | Female | 74 | Ever | 2 | Clinical trial | Combination | 4.63 | Progressed | NO | IMPACT341 | LUAD | 11.2245 | 0.03 | NA | Non-Small Cell Lung Cancer | Lung Adenocarcinoma | Not MET-Amp |
| P-0001836 | P-0001836-T01-IM3 | Female | 60 | Ever | 2 | Commercial | Monotherapy | 1.77 | Progressed | NO | IMPACT341 | LUAD | 23.4694 | 0.31 | NA | Non-Small Cell Lung Cancer | Lung Adenocarcinoma | Not MET-Amp |
| P-0001867 | P-0001867-T01-IM3 | Male | 70 | Ever | 3 | Commercial | Monotherapy | 4.2 | Progressed | NO | IMPACT341 | LUAD | 13.2653 | 0.5 | NA | Non-Small Cell Lung Cancer | Lung Adenocarcinoma | Not MET-Amp |
| P-0001955 | P-0001955-T01-IM3 | Female | 31 | Never | 3 | Commercial | Monotherapy | 3.03 | Progressed | NO | IMPACT341 | LUAD | 2.0408 | 0.77 | 0 | Non-Small Cell Lung Cancer | Lung Adenocarcinoma | Not MET-Amp |
| P-0001977 | P-0001977-T01-IM3 | Male | 80 | Ever | 2 | Commercial | Monotherapy | 1.3 | Progressed | NO | IMPACT341 | LUAD | 9.1837 | 0.05 | NA | Non-Small Cell Lung Cancer | Lung Adenocarcinoma | Not MET-Amp |
| P-0002028 | P-0002028-T01-IM3 | Female | 64 | Ever | 3 | Commercial | Monotherapy | 25.03 | Not Progressed | YES | IMPACT341 | LUSC | 6.1224 | 0.23 | NA | Non-Small Cell Lung Cancer | Lung Squamous Cell Carcinoma | Not MET-Amp |
| P-0002151 | P-0002151-T01-IM3 | Female | 71 | Ever | 3 | Commercial | Monotherapy | 9.6 | Progressed | YES | IMPACT341 | LUAD | 9.1837 | 0.09 | NA | Non-Small Cell Lung Cancer | Lung Adenocarcinoma | Not MET-Amp |
| P-0002160 | P-0002160-T01-IM3 | Male | 66 | Ever | 3 | Commercial | Monotherapy | 1.27 | Progressed | NO | IMPACT341 | LUAD | 12.2449 | 0.18 | NA | Non-Small Cell Lung Cancer | Lung Adenocarcinoma | Not MET-Amp |
| P-0002225 | P-0002225-T02-IM5 | Male | 71 | Never | 2 | Commercial | Monotherapy | 2.57 | Progressed | NO | IMPACT410 | LUSC | 2.8302 | 0.13 | NA | Non-Small Cell Lung Cancer | Lung Squamous Cell Carcinoma | Not MET-Amp |
| P-0002247 | P-0002247-T01-IM3 | Female | 69 | Ever | 3 | Commercial | Monotherapy | 2.77 | Progressed | NO | IMPACT341 | LUAD | 19.3878 | 0.05 | 20 | Non-Small Cell Lung Cancer | Lung Adenocarcinoma | Not MET-Amp |
| P-0002252 | P-0002252-T01-IM3 | Female | 73 | Ever | 2 | Commercial | Monotherapy | 4.27 | Progressed | NO | IMPACT341 | LUSC | 15.3061 | 0.66 | NA | Non-Small Cell Lung Cancer | Lung Squamous Cell Carcinoma | Not MET-Amp |
| P-0002295 | P-0002295-T01-IM3 | Female | 75 | Never | 7 | Clinical trial | Monotherapy | 1.93 | Progressed | NO | IMPACT341 | LUAD | 4.0816 | 0.34 | 0 | Non-Small Cell Lung Cancer | Lung Adenocarcinoma | Not MET-Amp |
| P-0002320 | P-0002320-T01-IM3 | Male | 57 | Never | 2 | Commercial | Monotherapy | 1.77 | Progressed | NO | IMPACT341 | LUAD | 6.1224 | 0.11 | NA | Non-Small Cell Lung Cancer | Lung Adenocarcinoma | Not MET-Amp |
| P-0002351 | P-0002351-T01-IM3 | Female | 74 | Ever | 3 | Commercial | Monotherapy | 5.37 | Progressed | NO | IMPACT341 | LUSC | 7.1429 | 0.09 | NA | Non-Small Cell Lung Cancer | Lung Squamous Cell Carcinoma | Not MET-Amp |
| P-0002444 | P-0002444-T01-IM3 | Male | 66 | Ever | 3 | Commercial | Monotherapy | 2.1 | Progressed | NO | IMPACT341 | LUAD | 16.3265 | 0.4 | NA | Non-Small Cell Lung Cancer | Lung Adenocarcinoma | Not MET-Amp |
| P-0002485 | P-0002485-T01-IM3 | Male | 43 | Ever | 1 | Clinical trial | Monotherapy | 7.5 | Progressed | YES | IMPACT341 | LUSC | 3.0612 | 0.03 | 0 | Non-Small Cell Lung Cancer | Lung Squamous Cell Carcinoma | Not MET-Amp |
| P-0002546 | P-0002546-T01-IM3 | Male | 67 | Ever | 1 | Clinical trial | Combination | 7.9 | Progressed | YES | IMPACT341 | LUAD | 2.0408 | 0.04 | NA | Non-Small Cell Lung Cancer | Lung Adenocarcinoma | Not MET-Amp |
| P-0002559 | P-0002559-T01-IM3 | Female | 37 | Never | 1 | Clinical trial | Monotherapy | 1.07 | Progressed | NO | IMPACT341 | LUAD | 1.0204 | 0.14 | NA | Non-Small Cell Lung Cancer | Lung Adenocarcinoma | Not MET-Amp |
| P-0002637 | P-0002637-T01-IM3 | Male | 53 | Ever | 1 | Clinical trial | Combination | 27.6 | Not Progressed | YES | IMPACT341 | LUNE | 17.3469 | 0.64 | 0 | Non-Small Cell Lung Cancer | Large Cell Neuroendocrine Carcinoma | Not MET-Amp |
| P-0002639 | P-0002639-T01-IM3 | Female | 67 | Ever | 2 | Commercial | Monotherapy | 8.1 | Not Progressed | YES | IMPACT341 | LUAD | 11.2245 | 0.04 | NA | Non-Small Cell Lung Cancer | Lung Adenocarcinoma | Not MET-Amp |
| P-0002731 | P-0002731-T02-IM5 | Female | 64 | Ever | 2 | Commercial | Monotherapy | 15.03 | Not Progressed | YES | IMPACT410 | LUAD | 9.434 | 0.56 | NA | Non-Small Cell Lung Cancer | Lung Adenocarcinoma | Not MET-Amp |
| P-0002751 | P-0002751-T01-IM3 | Female | 68 | Ever | 1 | Clinical trial | Monotherapy | 4.43 | Progressed | NO | IMPACT341 | LUAD | 2.0408 | 0.11 | 20 | Non-Small Cell Lung Cancer | Lung Adenocarcinoma | Not MET-Amp |
| P-0002758 | P-0002758-T01-IM3 | Male | 62 | Ever | 3 | Commercial | Monotherapy | 1.8 | Progressed | NO | IMPACT341 | NSCLC | 32.6531 | 0.23 | NA | Non-Small Cell Lung Cancer | Non-Small Cell Lung Cancer | Not MET-Amp |
| P-0002766 | P-0002766-T01-IM3 | Female | 66 | Ever | 2 | Commercial | Monotherapy | 1.57 | Progressed | NO | IMPACT341 | LUAD | 6.1224 | 0.05 | 5 | Non-Small Cell Lung Cancer | Lung Adenocarcinoma | Not MET-Amp |
| P-0002794 | P-0002794-T02-IM5 | Female | 61 | Ever | 2 | Commercial | Monotherapy | 15.97 | Progressed | YES | IMPACT410 | LUAD | 8.4906 | 0.06 | NA | Non-Small Cell Lung Cancer | Lung Adenocarcinoma | Not MET-Amp |
| P-0002806 | P-0002806-T01-IM3 | Male | 80 | Ever | 1 | Clinical trial | Monotherapy | 8.3 | Progressed | YES | IMPACT341 | LUAD | 4.0816 | 0.19 | 0 | Non-Small Cell Lung Cancer | Lung Adenocarcinoma | Not MET-Amp |
| P-0002826 | P-0002826-T01-IM3 | Female | 61 | Ever | 3 | Clinical trial | Monotherapy | 1.57 | Progressed | NO | IMPACT341 | LUAD | 13.2653 | 0.51 | NA | Non-Small Cell Lung Cancer | Lung Adenocarcinoma | Not MET-Amp |
| P-0002874 | P-0002874-T01-IM3 | Female | 55 | Ever | 4 | Commercial | Monotherapy | 1.03 | Progressed | NO | IMPACT341 | LUAD | 13.2653 | 0.43 | NA | Non-Small Cell Lung Cancer | Lung Adenocarcinoma | Not MET-Amp |
| P-0002890 | P-0002890-T01-IM3 | Female | 40 | Never | 4 | Commercial | Monotherapy | 0.37 | Progressed | NO | IMPACT341 | LUAD | 6.1224 | 0.2 | NA | Non-Small Cell Lung Cancer | Lung Adenocarcinoma | Not MET-Amp |
| P-0002905 | P-0002905-T01-IM3 | Male | 73 | Ever | 3 | Commercial | Monotherapy | 1.63 | Progressed | NO | IMPACT341 | LUAD | 5.102 | 0.2 | NA | Non-Small Cell Lung Cancer | Lung Adenocarcinoma | Not MET-Amp |
| P-0002912 | P-0002912-T01-IM3 | Male | 22 | Never | 3 | Clinical trial | Combination | 4.33 | Progressed | NO | IMPACT341 | LUAD | 2.0408 | 0.07 | NA | Non-Small Cell Lung Cancer | Lung Adenocarcinoma | Not MET-Amp |
| P-0002917 | P-0002917-T01-IM3 | Female | 51 | Ever | 2 | Commercial | Monotherapy | 2.57 | Progressed | NO | IMPACT341 | LUAD | 6.1224 | 0.28 | NA | Non-Small Cell Lung Cancer | Lung Adenocarcinoma | Not MET-Amp |
| P-0002921 | P-0002921-T01-IM3 | Female | 73 | Ever | 2 | Commercial | Monotherapy | 6.63 | Progressed | YES | IMPACT341 | LUAD | 13.2653 | 0.08 | 0 | Non-Small Cell Lung Cancer | Lung Adenocarcinoma | Not MET-Amp |
| P-0002965 | P-0002965-T01-IM3 | Male | 56 | Ever | 1 | Clinical trial | Monotherapy | 1.17 | Progressed | NO | IMPACT341 | LUSC | 7.1429 | 0.06 | NA | Non-Small Cell Lung Cancer | Lung Squamous Cell Carcinoma | Not MET-Amp |
| P-0002969 | P-0002969-T01-IM3 | Male | 56 | Ever | 4 | Commercial | Monotherapy | 0.73 | Progressed | NO | IMPACT341 | LUAD | 20.4082 | 0.11 | NA | Non-Small Cell Lung Cancer | Lung Adenocarcinoma | Not MET-Amp |
| P-0003017 | P-0003017-T01-IM3 | Female | 81 | Never | 5 | Commercial | Monotherapy | 6.13 | Progressed | YES | IMPACT341 | LUAD | 4.0816 | 0.01 | 0 | Non-Small Cell Lung Cancer | Lung Adenocarcinoma | Not MET-Amp |
| P-0003034 | P-0003034-T01-IM5 | Male | 80 | Ever | 4 | Commercial | Monotherapy | 3.6 | Progressed | NO | IMPACT410 | LUAD | 13.2075 | 0.44 | NA | Non-Small Cell Lung Cancer | Lung Adenocarcinoma | Not MET-Amp |
| P-0003132 | P-0003132-T01-IM5 | Female | 67 | Ever | 2 | Commercial | Monotherapy | 1.83 | Progressed | NO | IMPACT410 | LUSC | 34.9057 | 0.29 | 50 | Non-Small Cell Lung Cancer | Lung Squamous Cell Carcinoma | Not MET-Amp |
| P-0003157 | P-0003157-T01-IM5 | Male | 63 | Never | 2 | Commercial | Monotherapy | 0.77 | Progressed | NO | IMPACT410 | LUSC | 5.6604 | 0 | NA | Non-Small Cell Lung Cancer | Lung Squamous Cell Carcinoma | Not MET-Amp |
| P-0003229 | P-0003229-T01-IM5 | Male | 60 | Ever | 6 | Commercial | Monotherapy | 19.77 | Not Progressed | YES | IMPACT410 | LUAD | 48.1132 | 0.02 | 10 | Non-Small Cell Lung Cancer | Lung Adenocarcinoma | Not MET-Amp |
| P-0003275 | P-0003275-T01-IM5 | Male | 69 | Ever | 2 | Commercial | Monotherapy | 5.53 | Progressed | NO | IMPACT410 | LUAD | 2.8302 | 0 | 0 | Non-Small Cell Lung Cancer | Lung Adenocarcinoma | Not MET-Amp |
| P-0003322 | P-0003322-T01-IM5 | Female | 73 | Never | 4 | Commercial | Combination | 4.23 | Not Progressed | NE | IMPACT410 | LUAD | 2.8302 | 0.03 | NA | Non-Small Cell Lung Cancer | Lung Adenocarcinoma | Not MET-Amp |
| P-0003347 | P-0003347-T01-IM5 | Male | 58 | Ever | 2 | Clinical trial | Monotherapy | 6.17 | Progressed | YES | IMPACT410 | LUSC | 15.0943 | 0.65 | 30 | Non-Small Cell Lung Cancer | Lung Squamous Cell Carcinoma | Not MET-Amp |
| P-0003368 | P-0003368-T01-IM5 | Female | 57 | Ever | 1 | Clinical trial | Combination | 30.47 | Not Progressed | YES | IMPACT410 | LUAD | 8.4906 | 0 | 95 | Non-Small Cell Lung Cancer | Lung Adenocarcinoma | Not MET-Amp |
| P-0003495 | P-0003495-T01-IM5 | Female | 92 | Never | 5 | Commercial | Monotherapy | 8.67 | Progressed | YES | IMPACT410 | LUAD | 3.7736 | 0.03 | NA | Non-Small Cell Lung Cancer | Lung Adenocarcinoma | Not MET-Amp |
| P-0003562 | P-0003562-T02-IM5 | Female | 60 | Ever | 1 | Clinical trial | Monotherapy | 9.2 | Progressed | YES | IMPACT410 | LUAD | 34.9057 | 0.45 | NA | Non-Small Cell Lung Cancer | Lung Adenocarcinoma | Not MET-Amp |
| P-0003584 | P-0003584-T01-IM5 | Male | 59 | Ever | 1 | Clinical trial | Monotherapy | 8.33 | Progressed | YES | IMPACT410 | LUAD | 10.3774 | 0.02 | 40 | Non-Small Cell Lung Cancer | Lung Adenocarcinoma | Not MET-Amp |
| P-0003735 | P-0003735-T01-IM5 | Female | 68 | Ever | 3 | Commercial | Monotherapy | 0.87 | Progressed | NO | IMPACT410 | LUAD | 0.9434 | 0.01 | 0 | Non-Small Cell Lung Cancer | Lung Adenocarcinoma | Not MET-Amp |
| P-0003738 | P-0003738-T02-IM5 | Female | 57 | Never | 2 | Commercial | Monotherapy | 10.4 | Progressed | YES | IMPACT410 | LUAD | 4.717 | 0 | NA | Non-Small Cell Lung Cancer | Lung Adenocarcinoma | Not MET-Amp |
| P-0003782 | P-0003782-T01-IM5 | Male | 58 | Ever | 2 | Commercial | Monotherapy | 3.1 | Progressed | NO | IMPACT410 | LUAD | 2.8302 | 0.01 | NA | Non-Small Cell Lung Cancer | Lung Adenocarcinoma | Not MET-Amp |
| P-0003869 | P-0003869-T01-IM5 | Female | 66 | Ever | 1 | Clinical trial | Monotherapy | 5.47 | Progressed | NO | IMPACT410 | LUAD | 52.8302 | 0.33 | 0 | Non-Small Cell Lung Cancer | Lung Adenocarcinoma | Not MET-Amp |
| P-0003913 | P-0003913-T01-IM3 | Female | 44 | Never | 5 | Commercial | Monotherapy | 0.4 | Progressed | NO | IMPACT341 | LUAD | 3.0612 | 0.28 | NA | Non-Small Cell Lung Cancer | Lung Adenocarcinoma | Not MET-Amp |
| P-0003964 | P-0003964-T01-IM3 | Male | 73 | Ever | 3 | Commercial | Monotherapy | 2.8 | Progressed | NO | IMPACT341 | LUAD | 9.1837 | 0.13 | 1 | Non-Small Cell Lung Cancer | Lung Adenocarcinoma | Not MET-Amp |
| P-0003970 | P-0003970-T02-IM5 | Female | 47 | Never | 5 | Commercial | Monotherapy | 5.83 | Not Progressed | NE | IMPACT410 | LUAD | 1.8868 | 0.01 | NA | Non-Small Cell Lung Cancer | Lung Adenocarcinoma | Not MET-Amp |
| P-0004020 | P-0004020-T01-IM5 | Female | 58 | Ever | 1 | Clinical trial | Combination | 5.13 | Progressed | NO | IMPACT410 | LUAD | 4.717 | 0.03 | NA | Non-Small Cell Lung Cancer | Lung Adenocarcinoma | Not MET-Amp |
| P-0004054 | P-0004054-T01-IM5 | Male | 61 | Ever | 2 | Commercial | Monotherapy | 3.17 | Progressed | NO | IMPACT410 | LUAD | 13.2075 | 0.48 | NA | Non-Small Cell Lung Cancer | Lung Adenocarcinoma | Not MET-Amp |
| P-0004232 | P-0004232-T01-IM5 | Male | 75 | Ever | 5 | Commercial | Monotherapy | 4.63 | Progressed | NO | IMPACT410 | LUAD | 6.6038 | 0.24 | NA | Non-Small Cell Lung Cancer | Lung Adenocarcinoma | Not MET-Amp |
| P-0004279 | P-0004279-T01-IM5 | Female | 59 | Never | 3 | Commercial | Monotherapy | 1.8 | Progressed | NO | IMPACT410 | LUAD | 2.8302 | 0.43 | 0 | Non-Small Cell Lung Cancer | Lung Adenocarcinoma | Not MET-Amp |
| P-0004436 | P-0004436-T01-IM5 | Male | 75 | Ever | 2 | Commercial | Monotherapy | 1.83 | Progressed | NO | IMPACT410 | LUAD | 5.6604 | 0.36 | NA | Non-Small Cell Lung Cancer | Lung Adenocarcinoma | Not MET-Amp |
| P-0004442 | P-0004442-T01-IM5 | Male | 62 | Ever | 1 | Commercial | Monotherapy | 3.3 | Progressed | NO | IMPACT410 | LUAD | 33.0189 | 0.15 | NA | Non-Small Cell Lung Cancer | Lung Adenocarcinoma | Not MET-Amp |
| P-0004463 | P-0004463-T01-IM5 | Male | 82 | Never | 2 | Commercial | Monotherapy | 1.57 | Progressed | NO | IMPACT410 | LUAD | 6.6038 | 0.2 | NA | Non-Small Cell Lung Cancer | Lung Adenocarcinoma | Not MET-Amp |
| P-0004472 | P-0004472-T01-IM5 | Female | 62 | Ever | 2 | Commercial | Monotherapy | 4 | Progressed | NO | IMPACT410 | LUAD | 14.1509 | 0.31 | NA | Non-Small Cell Lung Cancer | Lung Adenocarcinoma | Not MET-Amp |
| P-0004495 | P-0004495-T01-IM5 | Male | 40 | Ever | 2 | Commercial | Monotherapy | 1.07 | Progressed | NO | IMPACT410 | LUSC | 8.4906 | 0 | NA | Non-Small Cell Lung Cancer | Lung Squamous Cell Carcinoma | Not MET-Amp |
| P-0004517 | P-0004517-T01-IM5 | Male | 67 | Never | 2 | Commercial | Monotherapy | 1.67 | Progressed | NO | IMPACT410 | LUSC | 14.1509 | 0.38 | 0 | Non-Small Cell Lung Cancer | Lung Squamous Cell Carcinoma | Not MET-Amp |
| P-0004588 | P-0004588-T01-IM5 | Male | 73 | Ever | 3 | Commercial | Monotherapy | 20.2 | Not Progressed | YES | IMPACT410 | LUAD | 3.7736 | 0 | NA | Non-Small Cell Lung Cancer | Lung Adenocarcinoma | Not MET-Amp |
| P-0004701 | P-0004701-T01-IM5 | Female | 52 | Ever | 2 | Commercial | Monotherapy | 20 | Not Progressed | YES | IMPACT410 | NSCLC | 18.8679 | 0.23 | NA | Non-Small Cell Lung Cancer | Non-Small Cell Lung Cancer | Not MET-Amp |
| P-0004752 | P-0004752-T01-IM5 | Male | 86 | Never | 3 | Commercial | Monotherapy | 1.8 | Progressed | NO | IMPACT410 | LUAD | 0.9434 | 0 | 0 | Non-Small Cell Lung Cancer | Lung Adenocarcinoma | Not MET-Amp |
| P-0004759 | P-0004759-T01-IM5 | Female | 63 | Ever | 2 | Commercial | Monotherapy | 0.67 | Progressed | NO | IMPACT410 | LUAD | 1.8868 | 0.28 | NA | Non-Small Cell Lung Cancer | Lung Adenocarcinoma | Not MET-Amp |
| P-0004827 | P-0004827-T01-IM5 | Male | 58 | Ever | 1 | Clinical trial | Monotherapy | 10.47 | Progressed | YES | IMPACT410 | LUSC | 8.4906 | 0.01 | NA | Non-Small Cell Lung Cancer | Lung Squamous Cell Carcinoma | Not MET-Amp |
| P-0004890 | P-0004890-T01-IM5 | Female | 69 | Ever | 2 | Commercial | Monotherapy | 1.83 | Progressed | NO | IMPACT410 | LUAD | 11.3208 | 0.56 | NA | Non-Small Cell Lung Cancer | Lung Adenocarcinoma | Not MET-Amp |
| P-0004961 | P-0004961-T02-IM5 | Female | 69 | Ever | 3 | Commercial | Monotherapy | 4.37 | Progressed | NO | IMPACT410 | LUAD | 4.717 | 0.23 | NA | Non-Small Cell Lung Cancer | Lung Adenocarcinoma | Not MET-Amp |
| P-0004996 | P-0004996-T02-IM5 | Male | 54 | Never | 1 | Clinical trial | Combination | 1.83 | Progressed | NO | IMPACT410 | LUSC | 2.8302 | 0.27 | 75 | Non-Small Cell Lung Cancer | Lung Squamous Cell Carcinoma | Not MET-Amp |
| P-0005048 | P-0005048-T01-IM5 | Female | 68 | Never | 1 | Clinical trial | Combination | 15.07 | Progressed | YES | IMPACT410 | LUAD | 3.7736 | 0 | 75 | Non-Small Cell Lung Cancer | Lung Adenocarcinoma | Not MET-Amp |
| P-0005115 | P-0005115-T01-IM5 | Male | 55 | Ever | 2 | Commercial | Monotherapy | 1.83 | Progressed | NO | IMPACT410 | LUSC | 1.8868 | 0.19 | NA | Non-Small Cell Lung Cancer | Lung Squamous Cell Carcinoma | Not MET-Amp |
| P-0005289 | P-0005289-T01-IM5 | Male | 67 | Ever | 3 | Commercial | Monotherapy | 1.23 | Progressed | NO | IMPACT410 | LUAD | 9.434 | 0.14 | NA | Non-Small Cell Lung Cancer | Lung Adenocarcinoma | Not MET-Amp |
| P-0005295 | P-0005295-T01-IM5 | Male | 73 | Ever | 3 | Commercial | Monotherapy | 16.9 | Progressed | YES | IMPACT410 | LUAD | 3.7736 | 0.05 | NA | Non-Small Cell Lung Cancer | Lung Adenocarcinoma | Not MET-Amp |
| P-0005510 | P-0005510-T01-IM5 | Male | 67 | Ever | 4 | Clinical trial | Monotherapy | 21.13 | Progressed | YES | IMPACT410 | LUAD | 5.6604 | 0.04 | 1 | Non-Small Cell Lung Cancer | Lung Adenocarcinoma | Not MET-Amp |
| P-0005629 | P-0005629-T02-IM5 | Female | 81 | Ever | 2 | Commercial | Monotherapy | 1.73 | Progressed | NO | IMPACT410 | LUAD | 5.6604 | 0.02 | NA | Non-Small Cell Lung Cancer | Lung Adenocarcinoma | Not MET-Amp |
| P-0005721 | P-0005721-T01-IM5 | Male | 79 | Ever | 2 | Commercial | Monotherapy | 10.43 | Progressed | YES | IMPACT410 | LUAD | 6.6038 | 0.02 | NA | Non-Small Cell Lung Cancer | Lung Adenocarcinoma | Not MET-Amp |
| P-0005752 | P-0005752-T01-IM5 | Male | 64 | Ever | 5 | Clinical trial | Monotherapy | 1.8 | Progressed | NO | IMPACT410 | LUAD | 3.7736 | 0.02 | NA | Non-Small Cell Lung Cancer | Lung Adenocarcinoma | Not MET-Amp |
| P-0005792 | P-0005792-T01-IM5 | Male | 59 | Ever | 2 | Commercial | Monotherapy | 3.23 | Progressed | NO | IMPACT410 | LUSC | 10.3774 | 0.58 | NA | Non-Small Cell Lung Cancer | Lung Squamous Cell Carcinoma | Not MET-Amp |
| P-0005848 | P-0005848-T01-IM5 | Female | 81 | Ever | 2 | Commercial | Monotherapy | 8.63 | Not Progressed | YES | IMPACT410 | LUAD | 16.0377 | 0.09 | NA | Non-Small Cell Lung Cancer | Lung Adenocarcinoma | Not MET-Amp |
| P-0005898 | P-0005898-T01-IM5 | Female | 71 | Never | 2 | Commercial | Monotherapy | 12.53 | Progressed | YES | IMPACT410 | LUSC | 3.7736 | 0.18 | NA | Non-Small Cell Lung Cancer | Lung Squamous Cell Carcinoma | Not MET-Amp |
| P-0005975 | P-0005975-T01-IM5 | Female | 81 | Ever | 2 | Commercial | Monotherapy | 1.17 | Progressed | NO | IMPACT410 | LUAD | 10.3774 | 0.14 | 0 | Non-Small Cell Lung Cancer | Lung Adenocarcinoma | Not MET-Amp |
| P-0005981 | P-0005981-T01-IM5 | Male | 60 | Ever | 1 | Clinical trial | Monotherapy | 18.9 | Progressed | YES | IMPACT410 | LUAD | 9.434 | 0.11 | 50 | Non-Small Cell Lung Cancer | Lung Adenocarcinoma | Not MET-Amp |
| P-0006047 | P-0006047-T02-IM5 | Female | 62 | Never | 2 | Commercial | Monotherapy | 7.8 | Progressed | YES | IMPACT410 | LUAD | 1.8868 | 0 | NA | Non-Small Cell Lung Cancer | Lung Adenocarcinoma | Not MET-Amp |
| P-0006071 | P-0006071-T01-IM5 | Female | 53 | Ever | 2 | Commercial | Monotherapy | 4.73 | Progressed | NO | IMPACT410 | LUAD | 18.8679 | 0.49 | 0 | Non-Small Cell Lung Cancer | Lung Adenocarcinoma | Not MET-Amp |
| P-0006084 | P-0006084-T01-IM5 | Male | 62 | Never | 1 | Commercial | Monotherapy | 3.5 | Progressed | NO | IMPACT410 | LUAD | 6.6038 | 0.43 | 0 | Non-Small Cell Lung Cancer | Lung Adenocarcinoma | Not MET-Amp |
| P-0006114 | P-0006114-T02-IM5 | Female | 55 | Never | 3 | Commercial | Monotherapy | 1.8 | Progressed | NO | IMPACT410 | LUAD | 3.7736 | 0.13 | NA | Non-Small Cell Lung Cancer | Lung Adenocarcinoma | Not MET-Amp |
| P-0006294 | P-0006294-T01-IM5 | Female | 63 | Ever | 2 | Commercial | Monotherapy | 0.73 | Progressed | NO | IMPACT410 | LUAD | 3.7736 | 0.05 | NA | Non-Small Cell Lung Cancer | Lung Adenocarcinoma | Not MET-Amp |
| P-0006312 | P-0006312-T02-IM5 | Female | 51 | Never | 2 | Clinical trial | Combination | 15.3 | Not Progressed | YES | IMPACT410 | LUAD | 6.6038 | 0.19 | NA | Non-Small Cell Lung Cancer | Lung Adenocarcinoma | Not MET-Amp |
| P-0006330 | P-0006330-T01-IM5 | Male | 45 | Never | 2 | Commercial | Monotherapy | 5.4 | Progressed | NO | IMPACT410 | LUAD | 1.8868 | 0.31 | NA | Non-Small Cell Lung Cancer | Lung Adenocarcinoma | Not MET-Amp |
| P-0006343 | P-0006343-T01-IM5 | Female | 60 | Ever | 2 | Commercial | Monotherapy | 1.6 | Progressed | NO | IMPACT410 | LUAD | 5.6604 | 0.01 | 50 | Non-Small Cell Lung Cancer | Lung Adenocarcinoma | Not MET-Amp |
| P-0006364 | P-0006364-T01-IM5 | Male | 63 | Ever | 2 | Commercial | Monotherapy | 4.33 | Progressed | NO | IMPACT410 | LUAD | 4.717 | 0 | 1 | Non-Small Cell Lung Cancer | Lung Adenocarcinoma | Not MET-Amp |
| P-0006415 | P-0006415-T01-IM5 | Male | 86 | Ever | 2 | Commercial | Monotherapy | 1.97 | Progressed | NO | IMPACT410 | LUAD | 4.717 | 0.19 | NA | Non-Small Cell Lung Cancer | Lung Adenocarcinoma | Not MET-Amp |
| P-0006540 | P-0006540-T01-IM5 | Male | 70 | Ever | 1 | Clinical trial | Combination | 1.67 | Progressed | NO | IMPACT410 | LUSC | 11.3208 | 0 | NA | Non-Small Cell Lung Cancer | Lung Squamous Cell Carcinoma | Not MET-Amp |
| P-0006642 | P-0006642-T01-IM5 | Female | 68 | Ever | 2 | Commercial | Monotherapy | 2.7 | Progressed | NO | IMPACT410 | LUAD | 19.8113 | 0.16 | NA | Non-Small Cell Lung Cancer | Lung Adenocarcinoma | Not MET-Amp |
| P-0006724 | P-0006724-T01-IM5 | Female | 48 | Ever | 2 | Commercial | Monotherapy | 7.37 | Not Progressed | YES | IMPACT410 | NSCLC | 22.6415 | 0.61 | NA | Non-Small Cell Lung Cancer | Non-Small Cell Lung Cancer | Not MET-Amp |
| P-0006768 | P-0006768-T02-IM5 | Male | 66 | Ever | 1 | Commercial | Monotherapy | 4.27 | Progressed | NO | IMPACT410 | LUAD | 12.2642 | 0.54 | 0 | Non-Small Cell Lung Cancer | Lung Adenocarcinoma | Not MET-Amp |
| P-0006895 | P-0006895-T01-IM5 | Male | 65 | Ever | 2 | Commercial | Monotherapy | 9.37 | Not Progressed | YES | IMPACT410 | LUAD | 34.9057 | 0 | NA | Non-Small Cell Lung Cancer | Lung Adenocarcinoma | Not MET-Amp |
| P-0006954 | P-0006954-T01-IM5 | Female | 66 | Ever | 3 | Commercial | Monotherapy | 1.63 | Progressed | NO | IMPACT410 | LUAD | 7.5472 | 0.04 | NA | Non-Small Cell Lung Cancer | Lung Adenocarcinoma | Not MET-Amp |
| P-0006993 | P-0006993-T01-IM5 | Male | 68 | Ever | 3 | Commercial | Monotherapy | 1 | Progressed | NO | IMPACT410 | LUAD | 7.5472 | 0.16 | 0 | Non-Small Cell Lung Cancer | Lung Adenocarcinoma | Not MET-Amp |
| P-0007084 | P-0007084-T02-IM5 | Male | 83 | Ever | 1 | Clinical trial | Combination | 1.63 | Progressed | NO | IMPACT410 | LUAD | 8.4906 | 0.21 | 25 | Non-Small Cell Lung Cancer | Lung Adenocarcinoma | Not MET-Amp |
| P-0007088 | P-0007088-T02-IM5 | Female | 42 | Ever | 2 | Clinical trial | Monotherapy | 1.87 | Progressed | NO | IMPACT410 | LUAD | 4.717 | 0.41 | 2 | Non-Small Cell Lung Cancer | Lung Adenocarcinoma | Not MET-Amp |
| P-0007101 | P-0007101-T02-IM5 | Male | 76 | Ever | 2 | Commercial | Monotherapy | 1.7 | Progressed | NO | IMPACT410 | LUAD | 11.3208 | 0.3 | NA | Non-Small Cell Lung Cancer | Lung Adenocarcinoma | Not MET-Amp |
| P-0007121 | P-0007121-T01-IM5 | Female | 58 | Ever | 1 | Commercial | Monotherapy | 8.77 | Not Progressed | YES | IMPACT410 | LUAD | 7.5472 | 0 | 1 | Non-Small Cell Lung Cancer | Lung Adenocarcinoma | Not MET-Amp |
| P-0007123 | P-0007123-T01-IM5 | Female | 66 | Ever | 2 | Commercial | Monotherapy | 15.9 | Not Progressed | YES | IMPACT410 | LUAD | 8.4906 | 0.01 | NA | Non-Small Cell Lung Cancer | Lung Adenocarcinoma | Not MET-Amp |
| P-0007278 | P-0007278-T01-IM5 | Female | 55 | Ever | 3 | Commercial | Monotherapy | 2.57 | Progressed | NO | IMPACT410 | LUNE | 7.5472 | 0.01 | 0 | Non-Small Cell Lung Cancer | Large Cell Neuroendocrine Carcinoma | Not MET-Amp |
| P-0007418 | P-0007418-T01-IM5 | Female | 56 | Ever | 2 | Commercial | Monotherapy | 12.87 | Not Progressed | YES | IMPACT410 | LUAD | 16.0377 | 0.49 | NA | Non-Small Cell Lung Cancer | Lung Adenocarcinoma | Not MET-Amp |
| P-0007420 | P-0007420-T01-IM5 | Female | 85 | Ever | 2 | Commercial | Monotherapy | 2.37 | Progressed | NO | IMPACT410 | LUAD | 3.7736 | 0.25 | NA | Non-Small Cell Lung Cancer | Lung Adenocarcinoma | Not MET-Amp |
| P-0007493 | P-0007493-T02-IM5 | Male | 76 | Ever | 2 | Commercial | Monotherapy | 2.07 | Not Progressed | NE | IMPACT410 | LUAD | 17.9245 | 0.46 | 95 | Non-Small Cell Lung Cancer | Lung Adenocarcinoma | Not MET-Amp |
| P-0007583 | P-0007583-T01-IM5 | Female | 69 | Ever | 2 | Commercial | Monotherapy | 1.63 | Progressed | NO | IMPACT410 | LUAD | 13.2075 | 0.28 | 50 | Non-Small Cell Lung Cancer | Lung Adenocarcinoma | Not MET-Amp |
| P-0007597 | P-0007597-T01-IM5 | Male | 73 | Ever | 2 | Commercial | Monotherapy | 1.17 | Progressed | NO | IMPACT410 | LUAD | 15.0943 | 0.45 | NA | Non-Small Cell Lung Cancer | Lung Adenocarcinoma | Not MET-Amp |
| P-0007619 | P-0007619-T01-IM5 | Male | 77 | Ever | 2 | Commercial | Monotherapy | 1.17 | Progressed | NO | IMPACT410 | LUAD | 9.434 | 0.1 | NA | Non-Small Cell Lung Cancer | Lung Adenocarcinoma | Not MET-Amp |
| P-0007633 | P-0007633-T01-IM5 | Male | 76 | Never | 1 | Clinical trial | Combination | 24.27 | Progressed | YES | IMPACT410 | LUAD | 2.8302 | 0.02 | NA | Non-Small Cell Lung Cancer | Lung Adenocarcinoma | Not MET-Amp |
| P-0007757 | P-0007757-T02-IM5 | Female | 37 | Ever | 2 | Clinical trial | Combination | 6.33 | Progressed | YES | IMPACT410 | NSCLC | 8.4906 | 0 | NA | Non-Small Cell Lung Cancer | Non-Small Cell Lung Cancer | Not MET-Amp |
| P-0007861 | P-0007861-T01-IM5 | Female | 76 | Never | 3 | Commercial | Monotherapy | 2.6 | Progressed | NO | IMPACT410 | LUAD | 2.8302 | 0.03 | 10 | Non-Small Cell Lung Cancer | Lung Adenocarcinoma | Not MET-Amp |
| P-0007879 | P-0007879-T01-IM5 | Female | 68 | Ever | 2 | Commercial | Monotherapy | 12.07 | Progressed | YES | IMPACT410 | LUAD | 9.434 | 0.42 | 90 | Non-Small Cell Lung Cancer | Lung Adenocarcinoma | Not MET-Amp |
| P-0007977 | P-0007977-T01-IM5 | Female | 69 | Ever | 2 | Commercial | Monotherapy | 1.63 | Progressed | NO | IMPACT410 | NSCLC | 5.6604 | 0.04 | NA | Non-Small Cell Lung Cancer | Non-Small Cell Lung Cancer | Not MET-Amp |
| P-0007978 | P-0007978-T01-IM5 | Female | 50 | Ever | 2 | Commercial | Monotherapy | 2.5 | Progressed | NO | IMPACT410 | LUAD | 10.3774 | 0.26 | NA | Non-Small Cell Lung Cancer | Lung Adenocarcinoma | Not MET-Amp |
| P-0008176 | P-0008176-T01-IM5 | Female | 71 | Never | 1 | Commercial | Monotherapy | 1.93 | Progressed | NO | IMPACT410 | LUAD | 3.7736 | 0.05 | 0 | Non-Small Cell Lung Cancer | Lung Adenocarcinoma | Not MET-Amp |
| P-0008239 | P-0008239-T01-IM5 | Female | 74 | Ever | 2 | Commercial | Monotherapy | 15.13 | Progressed | YES | IMPACT410 | LUSC | 15.0943 | 0.04 | NA | Non-Small Cell Lung Cancer | Lung Squamous Cell Carcinoma | Not MET-Amp |
| P-0008295 | P-0008295-T01-IM5 | Male | 57 | Ever | 1 | Commercial | Monotherapy | 3.17 | Progressed | NO | IMPACT410 | LUAD | 5.6604 | 0.79 | 0 | Non-Small Cell Lung Cancer | Lung Adenocarcinoma | Not MET-Amp |
| P-0008322 | P-0008322-T01-IM5 | Male | 66 | Ever | 2 | Commercial | Monotherapy | 2.1 | Not Progressed | NE | IMPACT410 | LUAD | 2.8302 | 0.22 | NA | Non-Small Cell Lung Cancer | Lung Adenocarcinoma | Not MET-Amp |
| P-0008370 | P-0008370-T01-IM5 | Female | 77 | Ever | 2 | Commercial | Monotherapy | 0.9 | Progressed | NO | IMPACT410 | LUAD | 6.6038 | 0.03 | NA | Non-Small Cell Lung Cancer | Lung Adenocarcinoma | Not MET-Amp |
| P-0008406 | P-0008406-T01-IM5 | Female | 67 | Ever | 4 | Commercial | Monotherapy | 1.17 | Progressed | NO | IMPACT410 | LUAD | 23.5849 | 0.46 | NA | Non-Small Cell Lung Cancer | Lung Adenocarcinoma | Not MET-Amp |
| P-0008442 | P-0008442-T02-IM5 | Female | 65 | Never | 2 | Commercial | Monotherapy | 1.4 | Progressed | NO | IMPACT410 | LUAD | 12.2642 | 0.03 | NA | Non-Small Cell Lung Cancer | Lung Adenocarcinoma | Not MET-Amp |
| P-0008715 | P-0008715-T01-IM5 | Male | 73 | Ever | 1 | Clinical trial | Combination | 9.1 | Progressed | YES | IMPACT410 | LUAD | 17.9245 | 0.29 | NA | Non-Small Cell Lung Cancer | Lung Adenocarcinoma | Not MET-Amp |
| P-0008786 | P-0008786-T01-IM5 | Male | 64 | Never | 2 | Commercial | Monotherapy | 1.87 | Not Progressed | NE | IMPACT410 | LUAD | 4.717 | 0.69 | NA | Non-Small Cell Lung Cancer | Lung Adenocarcinoma | Not MET-Amp |
| P-0008848 | P-0008848-T01-IM5 | Male | 76 | Ever | 2 | Commercial | Monotherapy | 1.33 | Progressed | NO | IMPACT410 | LUNE | 5.6604 | 0.19 | NA | Non-Small Cell Lung Cancer | Large Cell Neuroendocrine Carcinoma | Not MET-Amp |
| P-0008851 | P-0008851-T01-IM5 | Male | 63 | Ever | 1 | Commercial | Monotherapy | 1.4 | Progressed | NO | IMPACT410 | NSCLC | 7.5472 | 0.07 | 10 | Non-Small Cell Lung Cancer | Non-Small Cell Lung Cancer | Not MET-Amp |
| P-0008935 | P-0008935-T01-IM5 | Female | 74 | Ever | 3 | Commercial | Monotherapy | 3.07 | Progressed | NO | IMPACT410 | LUAD | 10.3774 | 0.11 | NA | Non-Small Cell Lung Cancer | Lung Adenocarcinoma | Not MET-Amp |
| P-0008944 | P-0008944-T01-IM5 | Female | 46 | Ever | 1 | Commercial | Monotherapy | 1.6 | Progressed | NO | IMPACT410 | LUAD | 10.3774 | 0.04 | 100 | Non-Small Cell Lung Cancer | Lung Adenocarcinoma | Not MET-Amp |
| P-0008976 | P-0008976-T01-IM5 | Male | 83 | Ever | 2 | Clinical trial | Combination | 22.63 | Progressed | YES | IMPACT410 | LUAD | 7.5472 | 0.49 | NA | Non-Small Cell Lung Cancer | Lung Adenocarcinoma | Not MET-Amp |
| P-0009080 | P-0009080-T01-IM5 | Male | 74 | Ever | 2 | Commercial | Monotherapy | 1.87 | Progressed | NO | IMPACT410 | LUSC | 5.6604 | 0.3 | 0 | Non-Small Cell Lung Cancer | Lung Squamous Cell Carcinoma | Not MET-Amp |
| P-0009202 | P-0009202-T01-IM5 | Male | 66 | Ever | 2 | Commercial | Monotherapy | 3.47 | Not Progressed | NE | IMPACT410 | LUSC | 11.3208 | 0.29 | 60 | Non-Small Cell Lung Cancer | Lung Squamous Cell Carcinoma | Not MET-Amp |
| P-0009256 | P-0009256-T01-IM5 | Female | 75 | Ever | 2 | Commercial | Monotherapy | 7.47 | Progressed | YES | IMPACT410 | LUAD | 9.434 | 0.16 | 0 | Non-Small Cell Lung Cancer | Lung Adenocarcinoma | Not MET-Amp |
| P-0009274 | P-0009274-T01-IM5 | Female | 76 | Ever | 2 | Commercial | Combination | 1 | Progressed | NO | IMPACT410 | LUAD | 3.7736 | 0.46 | NA | Non-Small Cell Lung Cancer | Lung Adenocarcinoma | Not MET-Amp |
| P-0009293 | P-0009293-T01-IM5 | Female | 80 | Ever | 2 | Commercial | Monotherapy | 16.57 | Not Progressed | YES | IMPACT410 | LUAD | 20.7547 | 0.16 | 0 | Non-Small Cell Lung Cancer | Lung Adenocarcinoma | Not MET-Amp |
| P-0009319 | P-0009319-T01-IM5 | Male | 62 | Ever | 1 | Clinical trial | Combination | 13 | Progressed | YES | IMPACT410 | LUAD | 1.8868 | 0.29 | NA | Non-Small Cell Lung Cancer | Lung Adenocarcinoma | Not MET-Amp |
| P-0009379 | P-0009379-T01-IM5 | Male | 69 | Ever | 3 | Commercial | Monotherapy | 1.03 | Progressed | NO | IMPACT410 | LUAD | 9.434 | 0 | NA | Non-Small Cell Lung Cancer | Lung Adenocarcinoma | Not MET-Amp |
| P-0009419 | P-0009419-T01-IM5 | Male | 60 | Ever | 2 | Commercial | Monotherapy | 1.73 | Progressed | NO | IMPACT410 | LUAD | 12.2642 | 0 | NA | Non-Small Cell Lung Cancer | Lung Adenocarcinoma | Not MET-Amp |
| P-0009426 | P-0009426-T01-IM5 | Female | 64 | Ever | 6 | Commercial | Monotherapy | 5.53 | Progressed | NO | IMPACT410 | LUAD | 10.3774 | 0.22 | NA | Non-Small Cell Lung Cancer | Lung Adenocarcinoma | Not MET-Amp |
| P-0009469 | P-0009469-T01-IM5 | Female | 32 | Never | 2 | Commercial | Monotherapy | 2.73 | Progressed | NO | IMPACT410 | LUAD | 2.8302 | 0.36 | NA | Non-Small Cell Lung Cancer | Lung Adenocarcinoma | Not MET-Amp |
| P-0009473 | P-0009473-T01-IM5 | Male | 79 | Ever | 2 | Commercial | Monotherapy | 11.97 | Not Progressed | YES | IMPACT410 | LUAD | 8.4906 | 0.08 | NA | Non-Small Cell Lung Cancer | Lung Adenocarcinoma | Not MET-Amp |
| P-0009501 | P-0009501-T01-IM5 | Male | 72 | Ever | 2 | Commercial | Monotherapy | 2.6 | Progressed | NO | IMPACT410 | LUSC | 5.6604 | 0.18 | NA | Non-Small Cell Lung Cancer | Lung Squamous Cell Carcinoma | Not MET-Amp |
| P-0009505 | P-0009505-T01-IM5 | Female | 62 | Ever | 1 | Commercial | Monotherapy | 2.2 | Progressed | NO | IMPACT410 | LUAD | 2.8302 | 0.21 | NA | Non-Small Cell Lung Cancer | Lung Adenocarcinoma | Not MET-Amp |
| P-0009521 | P-0009521-T01-IM5 | Female | 74 | Ever | 2 | Commercial | Monotherapy | 2.47 | Progressed | NO | IMPACT410 | NSCLC | 1.8868 | 0.23 | NA | Non-Small Cell Lung Cancer | Non-Small Cell Lung Cancer | Not MET-Amp |
| P-0009586 | P-0009586-T01-IM5 | Female | 55 | Ever | 2 | Commercial | Monotherapy | 7.17 | Progressed | YES | IMPACT410 | LUAD | 11.3208 | 0.28 | NA | Non-Small Cell Lung Cancer | Lung Adenocarcinoma | Not MET-Amp |
| P-0009655 | P-0009655-T01-IM5 | Female | 68 | Ever | 1 | Clinical trial | Combination | 8.63 | Progressed | YES | IMPACT410 | LUAD | 2.8302 | 0.03 | 10 | Non-Small Cell Lung Cancer | Lung Adenocarcinoma | Not MET-Amp |
| P-0009680 | P-0009680-T01-IM5 | Female | 59 | Ever | 5 | Commercial | Monotherapy | 5.4 | Progressed | NO | IMPACT410 | LUAD | 5.6604 | 0.21 | 0 | Non-Small Cell Lung Cancer | Lung Adenocarcinoma | Not MET-Amp |
| P-0009763 | P-0009763-T01-IM5 | Female | 48 | Ever | 2 | Clinical trial | Combination | 1.57 | Progressed | NO | IMPACT410 | LUAD | 1.8868 | 0.02 | NA | Non-Small Cell Lung Cancer | Lung Adenocarcinoma | Not MET-Amp |
| P-0009764 | P-0009764-T01-IM5 | Female | 50 | Ever | 2 | Commercial | Monotherapy | 6.3 | Not Progressed | YES | IMPACT410 | LUAD | 21.6981 | 0.2 | NA | Non-Small Cell Lung Cancer | Lung Adenocarcinoma | Not MET-Amp |
| P-0009833 | P-0009833-T01-IM5 | Female | 54 | Ever | 2 | Commercial | Monotherapy | 10.4 | Progressed | YES | IMPACT410 | LUAD | 31.1321 | 0.34 | 0 | Non-Small Cell Lung Cancer | Lung Adenocarcinoma | Not MET-Amp |
| P-0009959 | P-0009959-T01-IM5 | Male | 66 | Ever | 2 | Commercial | Monotherapy | 5.87 | Progressed | NO | IMPACT410 | LUAD | 2.8302 | 0.2 | 0 | Non-Small Cell Lung Cancer | Lung Adenocarcinoma | Not MET-Amp |
| P-0010024 | P-0010024-T01-IM5 | Male | 80 | Ever | 2 | Commercial | Monotherapy | 16.73 | Not Progressed | YES | IMPACT410 | LUSC | 3.7736 | 0.04 | NA | Non-Small Cell Lung Cancer | Lung Squamous Cell Carcinoma | Not MET-Amp |
| P-0010025 | P-0010025-T01-IM5 | Female | 58 | Ever | 2 | Commercial | Monotherapy | 1.63 | Progressed | NO | IMPACT410 | LUAD | 10.3774 | 0.15 | NA | Non-Small Cell Lung Cancer | Lung Adenocarcinoma | Not MET-Amp |
| P-0010065 | P-0010065-T01-IM5 | Male | 39 | Ever | 2 | Commercial | Monotherapy | 7.53 | Not Progressed | YES | IMPACT410 | LUAD | 1.8868 | 0.02 | NA | Non-Small Cell Lung Cancer | Lung Adenocarcinoma | Not MET-Amp |
| P-0010213 | P-0010213-T01-IM5 | Female | 50 | Ever | 2 | Commercial | Monotherapy | 16.8 | Not Progressed | YES | IMPACT410 | LUAD | 15.0943 | 0.59 | NA | Non-Small Cell Lung Cancer | Lung Adenocarcinoma | Not MET-Amp |
| P-0010256 | P-0010256-T01-IM5 | Female | 72 | Ever | 2 | Commercial | Monotherapy | 3.1 | Progressed | NO | IMPACT410 | LUAD | 3.7736 | 0.02 | NA | Non-Small Cell Lung Cancer | Lung Adenocarcinoma | Not MET-Amp |
| P-0010636 | P-0010636-T01-IM5 | Male | 68 | Ever | 2 | Commercial | Monotherapy | 5.77 | Progressed | NO | IMPACT410 | LUSC | 6.6038 | 0.44 | 80 | Non-Small Cell Lung Cancer | Lung Squamous Cell Carcinoma | Not MET-Amp |
| P-0010648 | P-0010648-T01-IM5 | Male | 73 | Ever | 2 | Commercial | Monotherapy | 2.03 | Progressed | NO | IMPACT410 | LUAD | 1.8868 | 0.18 | 0 | Non-Small Cell Lung Cancer | Lung Adenocarcinoma | Not MET-Amp |
| P-0010715 | P-0010715-T01-IM5 | Male | 67 | Ever | 2 | Commercial | Combination | 2.77 | Not Progressed | NE | IMPACT410 | LUNE | 48.1132 | 0.52 | NA | Non-Small Cell Lung Cancer | Large Cell Neuroendocrine Carcinoma | Not MET-Amp |
| P-0010736 | P-0010736-T01-IM5 | Male | 78 | Ever | 1 | Clinical trial | Monotherapy | 9.8 | Progressed | YES | IMPACT410 | LUAD | 24.5283 | 0.14 | NA | Non-Small Cell Lung Cancer | Lung Adenocarcinoma | Not MET-Amp |
| P-0010760 | P-0010760-T01-IM5 | Male | 51 | Ever | 2 | Commercial | Monotherapy | 5.43 | Progressed | NO | IMPACT410 | LUAD | 4.717 | 0 | NA | Non-Small Cell Lung Cancer | Lung Adenocarcinoma | Not MET-Amp |
| P-0010840 | P-0010840-T02-IM5 | Female | 55 | Ever | 2 | Commercial | Monotherapy | 0.83 | Progressed | NO | IMPACT410 | LUAD | 10.3774 | 0.06 | 0 | Non-Small Cell Lung Cancer | Lung Adenocarcinoma | Not MET-Amp |
| P-0010891 | P-0010891-T01-IM5 | Female | 42 | Never | 3 | Commercial | Combination | 1.27 | Progressed | NO | IMPACT410 | LUAD | 0.9434 | 0 | 0 | Non-Small Cell Lung Cancer | Lung Adenocarcinoma | Not MET-Amp |
| P-0010986 | P-0010986-T01-IM5 | Female | 55 | Ever | 2 | Commercial | Monotherapy | 2.3 | Progressed | NO | IMPACT410 | LUAD | 7.5472 | 0.11 | NA | Non-Small Cell Lung Cancer | Lung Adenocarcinoma | Not MET-Amp |
| P-0011033 | P-0011033-T01-IM5 | Female | 62 | Never | 2 | Commercial | Monotherapy | 1.7 | Progressed | NO | IMPACT410 | LUAD | 1.8868 | 0.34 | NA | Non-Small Cell Lung Cancer | Lung Adenocarcinoma | Not MET-Amp |
| P-0011036 | P-0011036-T01-IM5 | Male | 55 | Ever | 2 | Commercial | Monotherapy | 1.8 | Progressed | NO | IMPACT410 | LUNE | 11.3208 | 0.56 | NA | Non-Small Cell Lung Cancer | Large Cell Neuroendocrine Carcinoma | Not MET-Amp |
| P-0011149 | P-0011149-T01-IM5 | Female | 58 | Ever | 2 | Commercial | Monotherapy | 2.47 | Progressed | NO | IMPACT410 | LUAD | 11.3208 | 0.17 | 0 | Non-Small Cell Lung Cancer | Lung Adenocarcinoma | Not MET-Amp |
| P-0011180 | P-0011180-T01-IM5 | Female | 60 | Never | 3 | Commercial | Monotherapy | 1.83 | Progressed | NO | IMPACT410 | LUAD | 1.8868 | 0.04 | NA | Non-Small Cell Lung Cancer | Lung Adenocarcinoma | Not MET-Amp |
| P-0011192 | P-0011192-T01-IM5 | Female | 74 | Ever | 2 | Commercial | Monotherapy | 2.27 | Progressed | NO | IMPACT410 | LUAD | 10.3774 | 0.03 | NA | Non-Small Cell Lung Cancer | Lung Adenocarcinoma | Not MET-Amp |
| P-0011244 | P-0011244-T01-IM5 | Male | 76 | Ever | 2 | Commercial | Monotherapy | 2.1 | Progressed | NO | IMPACT410 | LUSC | 2.8302 | 0 | NA | Non-Small Cell Lung Cancer | Lung Squamous Cell Carcinoma | Not MET-Amp |
| P-0011254 | P-0011254-T01-IM5 | Female | 56 | Ever | 2 | Clinical trial | Combination | 1.53 | Progressed | NO | IMPACT410 | LUAD | 7.5472 | 0.11 | NA | Non-Small Cell Lung Cancer | Lung Adenocarcinoma | Not MET-Amp |
| P-0011499 | P-0011499-T01-IM5 | Female | 71 | Ever | 1 | Commercial | Monotherapy | 2.27 | Progressed | NO | IMPACT410 | LUAD | 7.5472 | 0.07 | NA | Non-Small Cell Lung Cancer | Lung Adenocarcinoma | Not MET-Amp |
| P-0011541 | P-0011541-T01-IM5 | Female | 77 | Ever | 3 | Commercial | Monotherapy | 4.2 | Not Progressed | NE | IMPACT410 | LUAD | 3.7736 | 0.26 | NA | Non-Small Cell Lung Cancer | Lung Adenocarcinoma | Not MET-Amp |
| P-0011559 | P-0011559-T01-IM5 | Male | 72 | Ever | 2 | Commercial | Monotherapy | 5.37 | Progressed | NO | IMPACT410 | LUAD | 3.7736 | 0 | NA | Non-Small Cell Lung Cancer | Lung Adenocarcinoma | Not MET-Amp |
| P-0012076 | P-0012076-T01-IM5 | Male | 72 | Never | 2 | Clinical trial | Combination | 3.5 | Progressed | NO | IMPACT410 | LUAD | 4.717 | 0.02 | NA | Non-Small Cell Lung Cancer | Lung Adenocarcinoma | Not MET-Amp |
| P-0012192 | P-0012192-T02-IM5 | Female | 72 | Ever | 2 | Clinical trial | Combination | 12.8 | Not Progressed | YES | IMPACT410 | LUAD | 13.2075 | 0.34 | NA | Non-Small Cell Lung Cancer | Lung Adenocarcinoma | Not MET-Amp |
| P-0012373 | P-0012373-T01-IM5 | Male | 68 | Ever | 2 | Commercial | Monotherapy | 1.77 | Progressed | NO | IMPACT410 | LUAD | 37.7358 | 0.15 | NA | Non-Small Cell Lung Cancer | Lung Adenocarcinoma | Not MET-Amp |
| P-0012427 | P-0012427-T01-IM5 | Male | 66 | Ever | 2 | Commercial | Monotherapy | 1.7 | Progressed | NO | IMPACT410 | LUAD | 5.6604 | 0.01 | NA | Non-Small Cell Lung Cancer | Lung Adenocarcinoma | Not MET-Amp |
| P-0012629 | P-0012629-T01-IM5 | Male | 81 | Ever | 2 | Commercial | Monotherapy | 4.8 | Progressed | NO | IMPACT410 | NSCLC | 2.8302 | 0 | 100 | Non-Small Cell Lung Cancer | Non-Small Cell Lung Cancer | Not MET-Amp |
| P-0012729 | P-0012729-T01-IM5 | Male | 69 | Ever | 2 | Commercial | Monotherapy | 4.27 | Progressed | NO | IMPACT410 | LUAD | 6.6038 | 0 | NA | Non-Small Cell Lung Cancer | Lung Adenocarcinoma | Not MET-Amp |
| P-0012817 | P-0012817-T01-IM5 | Male | 54 | Ever | 2 | Commercial | Monotherapy | 7.2 | Not Progressed | YES | IMPACT410 | LUAD | 32.0755 | 0.04 | NA | Non-Small Cell Lung Cancer | Lung Adenocarcinoma | Not MET-Amp |
| P-0012846 | P-0012846-T01-IM5 | Female | 59 | Ever | 1 | Commercial | Monotherapy | 11.3 | Not Progressed | YES | IMPACT410 | LUAD | 7.5472 | 0 | NA | Non-Small Cell Lung Cancer | Lung Adenocarcinoma | Not MET-Amp |
| P-0012849 | P-0012849-T01-IM5 | Male | 57 | Ever | 2 | Commercial | Monotherapy | 1.7 | Progressed | NO | IMPACT410 | LUAD | 9.434 | 0.31 | 5 | Non-Small Cell Lung Cancer | Lung Adenocarcinoma | Not MET-Amp |
| P-0012866 | P-0012866-T01-IM5 | Female | 50 | Never | 3 | Commercial | Monotherapy | 2.9 | Progressed | NO | IMPACT410 | LUAD | 5.6604 | 0.17 | NA | Non-Small Cell Lung Cancer | Lung Adenocarcinoma | Not MET-Amp |
| P-0012908 | P-0012908-T01-IM5 | Male | 79 | Never | 2 | Commercial | Monotherapy | 3.6 | Progressed | NO | IMPACT410 | LUAD | 6.6038 | 0.08 | NA | Non-Small Cell Lung Cancer | Lung Adenocarcinoma | Not MET-Amp |
| P-0012931 | P-0012931-T01-IM5 | Male | 71 | Ever | 2 | Commercial | Monotherapy | 2 | Progressed | NO | IMPACT410 | LUSC | 9.434 | 0.25 | NA | Non-Small Cell Lung Cancer | Lung Squamous Cell Carcinoma | Not MET-Amp |
| P-0013653 | P-0013653-T01-IM5 | Female | 69 | Ever | 2 | Clinical trial | Combination | 5.43 | Progressed | NO | IMPACT410 | LUAD | 7.5472 | 0 | 0 | Non-Small Cell Lung Cancer | Lung Adenocarcinoma | Not MET-Amp |
| P-0014172 | P-0014172-T01-IM5 | Male | 83 | Ever | 1 | Commercial | Monotherapy | 3.77 | Progressed | NO | IMPACT410 | LUAD | 16.9811 | 0.27 | 25 | Non-Small Cell Lung Cancer | Lung Adenocarcinoma | Not MET-Amp |
| P-0014269 | P-0014269-T01-IM6 | Male | 74 | Ever | 2 | Commercial | Monotherapy | 1.7 | Progressed | NO | IMPACT468 | LUSC | 0.8197 | 0.03 | NA | Non-Small Cell Lung Cancer | Lung Squamous Cell Carcinoma | Not MET-Amp |
| P-0014451 | P-0014451-T01-IM6 | Female | 64 | Ever | 2 | Commercial | Monotherapy | 0.6 | Progressed | NO | IMPACT468 | LUAD | 9.0164 | 0.38 | 0 | Non-Small Cell Lung Cancer | Lung Adenocarcinoma | Not MET-Amp |
| P-0014529 | P-0014529-T01-IM6 | Female | 65 | Ever | 1 | Commercial | Monotherapy | 4.67 | Not Progressed | NE | IMPACT468 | LUSC | 20.4918 | 0.39 | 20 | Non-Small Cell Lung Cancer | Lung Squamous Cell Carcinoma | Not MET-Amp |
| P-0014599 | P-0014599-T01-IM6 | Male | 63 | Ever | 2 | Commercial | Monotherapy | 8.83 | Not Progressed | YES | IMPACT468 | LUSC | 13.9344 | 0.57 | NA | Non-Small Cell Lung Cancer | Lung Squamous Cell Carcinoma | Not MET-Amp |
| P-0014786 | P-0014786-T01-IM6 | Female | 65 | Ever | 2 | Commercial | Monotherapy | 1.87 | Progressed | NO | IMPACT468 | NSCLC | 10.6557 | 0.51 | NA | Non-Small Cell Lung Cancer | Non-Small Cell Lung Cancer | Not MET-Amp |
| P-0014818 | P-0014818-T01-IM6 | Male | 83 | Ever | 1 | Commercial | Monotherapy | 6.03 | Progressed | YES | IMPACT468 | LUAD | 27.0492 | 0.08 | NA | Non-Small Cell Lung Cancer | Lung Adenocarcinoma | Not MET-Amp |
| P-0015078 | P-0015078-T01-IM6 | Female | 69 | Ever | 2 | Commercial | Monotherapy | 2.37 | Progressed | NO | IMPACT468 | LUAD | 7.377 | 0.45 | 0 | Non-Small Cell Lung Cancer | Lung Adenocarcinoma | Not MET-Amp |
| P-0015531 | P-0015531-T01-IM6 | Female | 53 | Ever | 2 | Commercial | Monotherapy | 7.1 | Not Progressed | YES | IMPACT468 | LUSC | 4.918 | 0.44 | NA | Non-Small Cell Lung Cancer | Lung Squamous Cell Carcinoma | Not MET-Amp |
| P-0015556 | P-0015556-T01-IM6 | Male | 64 | Ever | 2 | Commercial | Monotherapy | 16.73 | Progressed | YES | IMPACT468 | LUAD | 4.0984 | 0.06 | NA | Non-Small Cell Lung Cancer | Lung Adenocarcinoma | Not MET-Amp |
| P-0015758 | P-0015758-T01-IM6 | Female | 88 | Ever | 1 | Commercial | Monotherapy | 4.07 | Not Progressed | NE | IMPACT468 | NSCLC | 4.918 | 0 | 95 | Non-Small Cell Lung Cancer | Non-Small Cell Lung Cancer | Not MET-Amp |
| P-0015771 | P-0015771-T01-IM6 | Male | 62 | Ever | 2 | Clinical trial | Combination | 3.43 | Progressed | NO | IMPACT468 | LUAD | 1.6393 | 0.09 | NA | Non-Small Cell Lung Cancer | Lung Adenocarcinoma | Not MET-Amp |
| P-0015780 | P-0015780-T01-IM6 | Male | 51 | Ever | 2 | Commercial | Monotherapy | 1.83 | Progressed | NO | IMPACT468 | LUAD | 5.7377 | 0.19 | 0 | Non-Small Cell Lung Cancer | Lung Adenocarcinoma | Not MET-Amp |
| P-0015785 | P-0015785-T01-IM6 | Female | 56 | Ever | 2 | Commercial | Monotherapy | 4.17 | Progressed | NO | IMPACT468 | LUAD | 20.4918 | 0.31 | NA | Non-Small Cell Lung Cancer | Lung Adenocarcinoma | Not MET-Amp |
| P-0015984 | P-0015984-T01-IM6 | Female | 66 | Ever | 2 | Commercial | Monotherapy | 1.63 | Progressed | NO | IMPACT468 | LUSC | 19.6721 | 0.62 | 5 | Non-Small Cell Lung Cancer | Lung Squamous Cell Carcinoma | Not MET-Amp |
| P-0016033 | P-0016033-T01-IM6 | Male | 72 | Ever | 1 | Commercial | Monotherapy | 5.5 | Not Progressed | NE | IMPACT468 | LUAD | 27.0492 | 0.17 | 90 | Non-Small Cell Lung Cancer | Lung Adenocarcinoma | Not MET-Amp |
| P-0016046 | P-0016046-T01-IM6 | Female | 68 | Never | 2 | Commercial | Monotherapy | 2.67 | Progressed | NO | IMPACT468 | LUAD | 4.918 | 0.12 | NA | Non-Small Cell Lung Cancer | Lung Adenocarcinoma | Not MET-Amp |
| P-0016646 | P-0016646-T01-IM6 | Male | 76 | Ever | 1 | Commercial | Monotherapy | 1.87 | Progressed | NO | IMPACT468 | LUAD | 8.1967 | 0.18 | 0 | Non-Small Cell Lung Cancer | Lung Adenocarcinoma | Not MET-Amp |
| P-0016809 | P-0016809-T01-IM6 | Female | 88 | Ever | 1 | Commercial | Monotherapy | 4.13 | Not Progressed | NE | IMPACT468 | NSCLC | 3.2787 | 0 | 60 | Non-Small Cell Lung Cancer | Non-Small Cell Lung Cancer | Not MET-Amp |